TheraRadar
← Back
Data updated: Jun 28, 2026

ADVANZ PHARMA

Big Pharma

ADVANZ PHARMA is a major pharmaceutical company focused on Oncology, Neurology, Cardiovascular.

1953
Since
11
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
9 Small Molecules

ADVANZ PHARMA's Key Drugs

ADVANZ PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ADVANZ PHARMA's Recent FDA Approvals

New NDA/BLA approvals for ADVANZ PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ADVANZ PHARMA's Therapeutic Areas

ADVANZ PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 9 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 43%
3 drugs
Neurology 14%
1 drugs
Cardiovascular 14%
1 drugs
Dermatology 14%
1 drugs
Immunology 14%
1 drugs

ADVANZ PHARMA's Top Competitors

ADVANZ PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ADVANZ PHARMA Pipeline Snapshot

Active clinical trials for ADVANZ PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling